Upload
others
View
6
Download
0
Embed Size (px)
Citation preview
Targeting Papillary
Kidney Cancer Variants
Brian Shuch, MD
Associate Professor of Urology
Director, Kidney Cancer Program
Alvin & Carrie Meinhardt Endowed Chair
in Kidney Cancer Research
1
“The Genetic Basis of RCC”
Clear Cell Papillary Type 1 Papillary Type 2 Chromophobe Oncocytoma
VHL MET FLCNFH
Linehan, WM, Walther, MM, Zbar, B. The genetic basis of cancer of
the kidney. The Journal of urology (2003) 170(6 Pt 1):2163-2172.
Reminisce to Simpler Times (Pre-TCGA)
3
Papillary RCC Are
Heterogenous
4Comprehensive Molecular Characterization of Papillary Renal-Cell
Carcinoma. (2015). Comprehensive Molecular Characterization of
Papillary Renal-Cell Carcinoma., 374(2), 135–145.
TCGA Expands Our Understanding of pRCC
What is recommended for “non-clear cell”
Clinical Trial Aiming to See The Standard of Care
S1500 Translational Objectives (Integrated Biomarkers)
Two integrated biomarkers are hypothesized to be both prognostic and
predictive in papillary kidney cancer patients treated with MET inhibitors.
1) Papillary subtype by central pathology review
• Type I versus Type II or NOS
2) MET Alteration Status including:
• MET mutation
• MET amplification
• MET mRNA overexpression
Ongoing Central Path Review
• Central review- 108 uploaded
• Challenging to call from 1-2
slides, immunostains, and path
report
• Poor Consensus: 36% with
complete agreement
Type 1 28
Type 2 49
Other 21
Pending Conference 10
S1500 Correlative Science
Biomarkers Approach
• Whole Exome Sequencing
• MET signaling pathway primary focus
• MET/HGF CNV changes (with confirmation via SNParray)
• Additional KIRP Genes
• Nanostring (dtRT-PCR)
• MET pathway gene set (GSEA=54)
• Exploratory aims:
-MET splice variants (seen in TCGA KIRP and other cohorts)
-MET kinase fusions (seen in various TCGA cohorts)
9
S1500 Correlative Science
Exploratory MET Activation: Splicing/Fusions
10
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C.
(2014). The landscape of kinase fusions in cancer. Nature
Communications, 5, 4846.
• splice variant missing exons
1&2 without extracellular
ligand binding domain
• 8 tumors (~5%) found with
novel MET splice variant
• cause ligand-independent
MET signaling
• 6 chimeric proteins found in TCGA
cohorts including KIRP follows the
classic activation paradigm, fusing
dimerization motifs to an intact
kinase domain
Its Not all About MET!
• While S1500 may establish a MET inhibitor as a standard of care for pRCC, its not expected to be a home run even for MET-driven tumors
• Need to better understand new targets/therapeutic approach
• A large well-annotated data and specimen collection will allow more rapid advancement in understanding aggressive pRCC
11
Validation of Prior Work with S1500 Cohort:
Whole Genome KIRP: Mutational Signatures
• Yale Team helped with Whole Genome analysis during TCGA KIRP
• Analysis not included in the NEJM paper
• Pattern of SNV may predict mechanism of tumorigenesis
• Additional work performed for signatures from WGS and WES
• ~20% with unique signature 3 “BRCAness”
• Some of these were the CIMP cohort
Li, S., Shuch, B. M., & Gerstein, M. B. (2017). Whole-genome analysis
of papillary kidney cancer finds significant noncoding alterations. PLoS
Genetics, 13(3)
Ranjit Bindra’s
Work in IDH1/2
(cholangio/glioma)
Relevant to
FH/SDH
Tumors?
UOK262 HLRCC
Model
Sulkowski, P. L., Sundaram, R. K., Oeck, S., Corso, C. D., Liu, Y.,
Noorbakhsh, S., et al. (2018). Krebs-cycle-deficient hereditary cancer
syndromes are defined by defects in homologous-recombination DNA
repair. Nat Genet, 31(8), 1578–1092.
SDH, FH, IDH1/2
Bench-to-bedside Approach
Additional Biomarker Analysis for S1500
• Reprocessing of Whole Exome Sequencing
• Mutational Signature including those with a possible HRD
• HLRCC and HLRCC-like pRCC
• Nanostring (dtRT-PCR)
• CIMP genes, HR genes, IO genes
• 500 gene classifier (TCGA signature) to molecular subclassify
• Mass Spec from Tissue
• Evaluate if linked to the CIMP/HLRCC phenotype
17
Mass Spec Analysis
from FFPE
18
FFPE samples from HLRCC kidney cancers
(high) and matched tumor/normal cases from
sporadic renal tumors.(less than lower limit of
quantification)
Conclusions • pRCC heterogenous disease
• Needs molecular characterization > Pathologic characterization
• MET inhibitor therapy may be a viable approach and be the standard of care but only a subset may benefit
• S1500 will allow robust correlative science to look at the MET pathway but will allow us to validate prelim work
• Some papillary variants may be HLRCC/HLRCC-like and may have an HR-Defect
• Treatment with PARP inhibitors promising, though we have only seen stable disease.
19